(iii) Natural MUC1 Abs from breast cancer patients reacted more strongly with GalNAc peptides than with the naked 60-mer peptide, indicating that a MUC1 glycopeptide could be a better vaccine [185]. This evidence concerns the gene MUC1 and breast carcinoma.